Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in diabetes management solutions, including insulin pumps and related technologies. The company operates in the healthcare sector, focusing on innovative products for diabetic patients.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.1% on May 20, 2026 15:36

• Tandem Diabetes Care (TNDM) experienced a bullish market movement today, likely driven by positive sentiment and confidence in the company's leadership and growth prospects.
• The routine equity compensation activities reported by TNDM's legal chief, CTO, and EVP may have instilled trust and stability among investors, showcasing commitment and alignment of interests with shareholders.
• The focus on the "Silver Economy" and the healthcare sector's growth opportunities, including TNDM's innovative initiatives, could have further boosted investor optimism and contributed to the stock's upward momentum.
• Despite a price target cut by B of A Securities, the overall positive industry outlook and company-specific developments seem to have outweighed this factor, leading to the bullish movement in TNDM's stock price.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care (TNDM) legal chief reports RSU vesting, tax withholding and ESPP purchase

Shannon M. Hansen, EVP & Chief Legal Officer at Tandem Diabetes Care (TNDM), reported routine equity compensation activities. These included the exercise of 10,201 restricted stock units (RSUs), with 5,192 shares withheld for tax obligations, and the purchase of 1,886 shares through the Employee Stock Purchase Plan (ESPP) at $10.90 per share. Following these transactions, Hansen directly holds 28,285 shares and indirectly holds 1,935 shares.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-bb9838e4eb31.html

Tandem Diabetes (TNDM) EVP reports RSU exercises, tax share withholding and trust holdings

Tandem Diabetes Care EVP Elizabeth Anne Gasser reported several compensation-related stock transactions on May 15, 2026, including the exercise of 10,267 restricted stock units and the receipt of an additional 1,337 shares. The company withheld 5,510 shares to cover tax obligations, with no shares sold by Gasser. Following these transactions, she directly holds 1,762 shares and indirectly holds 25,949 shares through The Gasser Family Trust.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-a26a1eae5071.html

Tandem Diabetes (TNDM) CTO reports RSU vesting, ESPP share purchase and tax withholding

Tandem Diabetes Care's EVP & CTO, Rick Carpenter, reported routine equity compensation activity, including the vesting of restricted stock units (RSUs) and an employee stock purchase plan (ESPP) acquisition. On May 15, 2026, he acquired 1,336 shares at $10.90 via ESPP and had 4,466 shares withheld at $12.82 for tax obligations related to RSU vestings, with no actual shares sold. Carpenter directly held 25,979 shares of Tandem Diabetes Care common stock after these transactions.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-26d966d1d8aa.html

Silver Economy Investing: Why the Healthcare Giants Are in Focus

The article discusses the "Silver Economy," highlighting how the rapidly aging global population is creating significant growth opportunities in the healthcare sector. It emphasizes how major healthcare companies like Eli Lilly, Tandem Diabetes Care, Intuitive Surgical, and ResMed are capitalizing on this demographic shift through innovation in areas such as obesity, diabetes, robotic surgery, and sleep health. The piece also details specific initiatives by these companies and outlines the financial resilience of the healthcare sector as an investment.

https://www.tradingview.com/news/zacks:fb0e329e1094b:0-silver-economy-investing-why-the-healthcare-giants-are-in-focus/

Tandem Diabetes Care Price Target Cut to $25.00/Share From $35.00 by B of A Securities

B of A Securities has lowered its price target for Tandem Diabetes Care (TNDM) from $35.00 to $25.00 per share. This adjustment reflects an updated outlook on the company's financial prospects, though the firm maintained a "Neutral" rating on the stock. The change indicates a revised valuation by B of A Securities for Tandem Diabetes Care.

https://www.moomoo.com/news/post/70195988/tandem-diabetes-care-price-target-cut-to-25-00-share?futusource=news_newspage_recommend

Trending Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 5.3% Today

International Business Machines Corporation ($IBM) Stock Forecast: Up 6.9% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 11.0% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.9% Today

Walmart Inc. ($WMT) Stock Forecast: Down 6.9% Today

Dow Jones Industrial Average ($INDU) Index Forecast: Up 0.8% Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Upwork Inc. ($UPWK) Stock Forecast: Up 5.3% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.5% Today

Tandem Diabetes Care, Inc. Price History

30.03.2026 - TNDM Stock was up 6.0%

• Tandem Diabetes Care disclosed upcoming conference appearances at two notable investor conferences, hinting at positive prospects and potentially exciting updates for investors.
• The FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes may have increased investor confidence in the company's innovative products and market potential.
• Vanguard Portfolio Management's substantial investment in Tandem Diabetes Care underscores investor interest and confidence in the company's future growth prospects.
• The overview of Tandem's market opportunity, dedication to innovation, and emphasis on commercial transformation likely contributed to the market's bullish trend as investors recognize the company's strong position in the global diabetes market.

30.03.2026 - TNDM Stock was up 7.6%

• Tandem Diabetes Care's stock experienced a strong bullish movement today.
• The bullish trend could be attributed to positive market sentiment driven by an increased price target for TNDM, highlighting the company's new pay-as-you-go program and Mobi Tubeless product as drivers for future revenue growth.
• Additionally, the FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes could have further boosted investor confidence in the company's innovative products and market potential.
• Significant stake in Tandem Diabetes Care Inc. by Vanguard Portfolio Management could also indicate institutional investor confidence in the company's long-term growth prospects.

13.04.2026 - TNDM Stock was down 5.5%

• Tandem Diabetes Care (TNDM) stock saw a significant decrease of 14.14% in after-hours trading, despite achieving record revenue and surpassing EPS estimates in Q1 2026.
• The initiation of coverage by Benchmark with a 'Hold' rating, showcasing varied analyst views and possible volatility, may have led to investor uncertainty.
• A research report by StockStory assigning an "Underperform" rating due to worries regarding modest sales growth and high valuation in comparison to business quality could have impacted the bearish trend.
• Despite making positive strides operationally and confirming full-year guidance, investor apprehensions about valuation, expense control, and long-term trends might have influenced the stock's decline.

01.04.2026 - TNDM Stock was up 7.7%

• Tandem Diabetes Care (TNDM) experienced a strong bullish movement recently.
• Vanguard Capital Management's significant passive institutional investment of over 3.5 million shares in TNDM may have instilled confidence in other investors, contributing to the bullish trend.
• The raised price target by TD Cowen and the positive outlook on TNDM's new products driving future revenue growth likely attracted more investors to the stock.
• The announcement of upcoming conference presentations by Tandem Diabetes Care could have also generated excitement and optimism among investors, further fueling the bullish momentum.

15.04.2026 - TNDM Stock was down 10.5%

• Tandem Diabetes Care (TNDM) posted a narrower loss, surpassed revenue expectations, and notably expanded its gross margin. Interestingly, the stock saw a significant 23.6% decline post-earnings, sparking speculation on potential factors:
• Market sentiment may have soured over doubts about the company's sustainability of growth or concerns regarding future sales performance, despite confirming its annual sales outlook.
• The 'Hold' rating from Benchmark upon initiating coverage, suggesting a balanced valuation and potential volatility, could have contributed to investor wariness, leading to downward stock pressure.
• Despite technical signals indicating a possible trend shift, a recent 26.5% decrease in TNDM's share price across four weeks might have influenced investor sentiment, prompting profit-taking and sell-offs.
• Ultimately, a blend of market sentiment, analyst evaluations, and technical indicators likely converged to shape a pessimistic short-term outlook for Tandem Diabetes Care (TNDM), contrasting with positive financial results and growth potential in the long run.

20.04.2026 - TNDM Stock was up 5.1%

• Tandem Diabetes Care (TNDM) experienced a bullish market movement today, likely driven by positive sentiment and confidence in the company's leadership and growth prospects.
• The routine equity compensation activities reported by TNDM's legal chief, CTO, and EVP may have instilled trust and stability among investors, showcasing commitment and alignment of interests with shareholders.
• The focus on the "Silver Economy" and the healthcare sector's growth opportunities, including TNDM's innovative initiatives, could have further boosted investor optimism and contributed to the stock's upward momentum.
• Despite a price target cut by B of A Securities, the overall positive industry outlook and company-specific developments seem to have outweighed this factor, leading to the bullish movement in TNDM's stock price.

08.04.2026 - TNDM Stock was down 9.7%

• Despite strong Q1 2026 financial results and strategic advancements, Tandem Diabetes Care's stock experienced a bearish movement.
• Concerns about the company's transition to a pay-as-you-go pharmacy model may have led to the market's negative reaction, with analysts predicting a potential near-term revenue decline and impact on earnings per share.
• Investors could be cautious due to short-term challenges from the operational shift, despite the company's positive long-term outlook and innovations in diabetes technology.
• The bearish movement might also result from profit-taking actions following the stock's recent strong performance and analyst upgrades, prompting investors to reassess their Tandem Diabetes Care positions.

04.04.2026 - TNDM Stock was down 5.0%

• A notable passive institutional investment by Vanguard Capital Management in Tandem Diabetes Care may have indicated lack of confidence in the company's future, influencing the bearish trend.
• Despite TD Cowen increasing TNDM's price target and maintaining a Buy rating, the market's negative reaction to the company's announcement of upcoming investor conference details might have led to market pessimism.
• Investors possibly engaged in profit-taking due to the anticipation of Tandem Diabetes Care's presentations at upcoming investor conferences, which could have driven down the stock price.
• Shifting market sentiment towards medical stocks priced below $30 could have impacted Tandem Diabetes Care's stock performance, notwithstanding positive forecasts for future revenue growth.

06.04.2026 - TNDM Stock was down 5.2%

• The FDA clearance for Tandem's Control-IQ+ technology for pregnant individuals with type 1 diabetes could have raised concerns among investors about potential regulatory and pricing pressures, leading to the bearish market movement.
• The disclosure of significant ownership stakes by institutional investors like Voya Financial and Vanguard Capital Management might have influenced market sentiment, contributing to the downward trend in TNDM stock.
• Despite TD Cowen raising Tandem Diabetes' price target and maintaining a Buy rating, the overall market reaction to the news about the pay-as-you-go program and Mobi Tubeless product may have been overshadowed by other factors, resulting in the bearish movement observed today.

11.04.2026 - TNDM Stock was down 6.2%

• Tandem Diabetes Care (TNDM) displayed a reduction in losses during Q4 2025, challenging bearish views and suggesting the potential for improved profit margins going forward.
• Mizuho Securities maintained a Hold rating on TNDM while increasing the target price to $24, reflecting their continuous evaluation of the company's financial outlook.
• Despite receiving FDA clearance for its Control-IQ+ technology for pregnancy use, TNDM's stock price has declined year-to-date, prompting discussions about undervaluation and a potential fair value of $30.76.
• Tandem Diabetes Care announced strong financial results for Q1 2026, including record pump shipments and sales, showcasing its dedication to innovation and expansion.

06.04.2026 - TNDM Stock was down 6.0%

• Investor concerns about potential dilution of existing shares following an upsized private placement of convertible senior notes may have influenced the negative market sentiment.
• Despite the FDA clearance for Control-IQ+ technology for pregnant individuals with type 1 diabetes, worries about execution risks related to new distribution models and regulatory pressures could have outweighed the positive news.
• The disclosure of substantial ownership stakes by institutional investors such as Voya Financial and Vanguard Capital Management could have led to increased selling pressure as some investors may view this as a lack of confidence in TNDM's short-term prospects.
• Insights driven by pricing data and AI-generated trading strategies pointing out choppy conditions and diverging sentiment across different time frames might have exacerbated uncertainty and contributed to the stock's bearish movement today.

12.04.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care reported impressive Q1 2026 earnings, beating estimates with a revenue of $247.22 million and an EPS of -$0.30, showing a 5.46% year-over-year increase. This positive financial performance likely fueled investor confidence and contributed to the bullish movement in the stock.
• Despite the record sales and positive operational progress, the stock initially dropped by 14.14% in after-hours trading, possibly due to investor concerns. However, the company's reaffirmation of its full-year guidance and growth expectations from new technologies and business models could have reassured investors, leading to the bullish trend.
• Truist Financial maintaining a Buy rating on Tandem Diabetes Care, albeit with a slightly reduced target price, indicates continued optimism in the company's future prospects. This vote of confidence might have further supported the bullish momentum in the stock.
• Tandem Diabetes Care's strategic initiatives, such as expanding internationally, launching new products like Control-IQ+ for pregnant women, and addressing supply chain challenges, demonstrate a proactive approach to growth. These factors, combined with the positive earnings report, likely contributed to the bullish market movement of the stock.